<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54308">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399137</url>
  </required_header>
  <id_info>
    <org_study_id>MM-141-07-02-02</org_study_id>
    <nct_id>NCT02399137</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer</brief_title>
  <acronym>CARRIE</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merrimack Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the combination of MM-141 plus
      nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone
      based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients
      with high serum levels of free IGF-1.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled Phase 2 study of MM-141 plus
      nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine in front-line
      metastatic pancreatic cancer. All patients will be initially screened for free IGF-1 status.
      Eligible patients with high free IGF-1 will be randomized to receive MM-141 plus
      nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine and patients.
      Patients with low free IGF-1 or patients who have high free IGF-1 but are not otherwise
      eligible will be followed in an observational group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Approximately 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Approximately 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate according to RECIST v1.1</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response according to RECIST v1.1</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events reported with the combination of MM-141 with nab-paclitaxel and gemcitabine versus the comparator arm</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A (Experimental Arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MM-141 in combination with nab-paclitaxel and gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Comparator Arm)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo in combination with nab-paclitaxel and gemcitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-141</intervention_name>
    <arm_group_label>Arm A (Experimental Arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Arm B (Comparator Arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Arm A (Experimental Arm)</arm_group_label>
    <arm_group_label>Arm B (Comparator Arm)</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <arm_group_label>Arm A (Experimental Arm)</arm_group_label>
    <arm_group_label>Arm B (Comparator Arm)</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic adenocarcinoma of the pancreas. Patients with islet cell neoplasms are not
             eligible.

          -  Patient must have received no prior radiotherapy, surgery, chemotherapy, or
             investigational therapy for the treatment of metastatic disease.

          -  Blood sample sent for free IGF-1 testing

          -  ECOG performance status (PS) of 0 or 1

        Exclusion Criteria:

          -  Patients who only present with localized disease

          -  Patients with CNS malignancies (primary or metastatic)

          -  Clinically significant cardiac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MM-141 Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merrimack Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Ctr.</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherril Bieman</last_name>
      <phone>480-256-4649</phone>
      <email>sherril.bierman@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Madappa N. Kundranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center, Inc.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Brown</last_name>
      <email>elizabethg@pacificcancer.com</email>
    </contact>
    <investigator>
      <last_name>Veena Charu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Yoon</last_name>
      <phone>714-446-5364</phone>
      <email>deborah.yoon@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>David Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Sanchez</last_name>
      <phone>310-633-8400</phone>
      <phone_ext>01466</phone_ext>
      <email>ajsanchez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Randolph Hecht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Assoc Med Grp</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Hutcherson</last_name>
      <phone>310-750-3376</phone>
      <email>shutcherson@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Hugo Hool, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariceli Alfaro</last_name>
      <phone>415-353-7284</phone>
      <email>Ariceli.Alfaro@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Ko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Cheek</last_name>
      <phone>805-898-3602</phone>
      <email>acheek@ccsb.org</email>
    </contact>
    <investigator>
      <last_name>Gregg Newman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Coast Med Onc Corp</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Fernandez</last_name>
      <phone>805-346-3461</phone>
      <email>alison.fernandez@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Dichmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujatha Nallapareddy</last_name>
      <email>sujatha.nallapareddy@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Health Med Gr Onc, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Ucar</last_name>
      <email>antonio.ucar@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer AffiliatesOcala</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ketan Doshi</last_name>
      <email>ketan.doshi@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Berbick</last_name>
      <phone>954-265-1864</phone>
      <email>sberbick@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Pablo Ferraro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America-Georgia</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Wilkinson</last_name>
      <phone>770-400-7191</phone>
      <email>gail.wilkinson@ctca-hope.com</email>
    </contact>
    <investigator>
      <last_name>Eyal Meiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Duffey</last_name>
      <phone>312-695-1102</phone>
      <email>s-duffey@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Halla Nimeiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Cabrales</last_name>
      <phone>312-413-1902</phone>
      <email>acabrals@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Arkadiusz Dudek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Siegel</last_name>
      <email>richard.siegel@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists, S.C.</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracey Hinshaw</last_name>
      <phone>847-410-0667</phone>
      <email>thinshaw@oncmed.net</email>
    </contact>
    <investigator>
      <last_name>Edward James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Regional Medical Cntr</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Ahn</last_name>
      <email>eugene.ahn@ctca-hope.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nylen Cancer Center</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Wender</last_name>
      <email>drednew@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Acadiana Research Department</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Maher</last_name>
      <email>smaher@guidestarclinical.com</email>
    </contact>
    <contact_backup>
      <phone>5047994400</phone>
      <phone_ext>4425</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Salman Malad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reliant Medical Group, Inc.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candace LeBlanc</last_name>
      <phone>508-556-5431</phone>
      <email>candace.leblanc@reliantmedicalgroup.org</email>
    </contact>
    <investigator>
      <last_name>James Rooney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compr Cancer Centers of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadi Braiteh</last_name>
      <email>fadi.braiteh@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Oncology HematologyPC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda DeMarco</last_name>
      <email>Linda.DeMarco@USOncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Inst</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Grande</last_name>
      <phone>716-845-8309</phone>
      <email>catherine.grande@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Patrick Boland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bassett Cancer Institute</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Bravin</last_name>
      <email>eric.bravin@bassett.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates, PC</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Marx</last_name>
      <phone>631-675-5143</phone>
      <email>dmarx@nshoa.com</email>
    </contact>
    <investigator>
      <last_name>David Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarina Dutta</last_name>
      <phone>212-342-4563</phone>
      <email>sd2941@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Oberstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Vulaj</last_name>
      <phone>212-342-0248</phone>
      <email>vv2218@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Oberstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Onco/ Zangmeister Ctr</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knoble Knoble</last_name>
      <email>jknoble@zangcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulsa Cancer Institute, PLLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Olsen</last_name>
      <email>mark.olsen@tciok.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Cressman</last_name>
      <phone>484-526-3589</phone>
      <email>karla.cressman@sluhn.org</email>
    </contact>
    <investigator>
      <last_name>Asim Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Friedant</last_name>
      <phone>215-214-1685</phone>
      <email>adam.friedant@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Crystal Denlinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dulabh Monga</last_name>
      <email>dmonga@wpahs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Ctr</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Taylor</last_name>
      <phone>615-875-0060</phone>
      <email>Kathy.l.taylor@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Emily Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCRI - Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Bendell</last_name>
      <email>jbendell@tnonc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Austin Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Cline-Burkhardt</last_name>
      <email>mika.cline-burkhardt@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology P A Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Anderson</last_name>
      <email>thomas.anderson@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Dallas P.H.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi McIntyre</last_name>
      <email>kristi.mcintyre@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center (BAMC)</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Anderson</last_name>
      <phone>210-916-3338</phone>
      <email>sanderson@hjf.org</email>
    </contact>
    <investigator>
      <last_name>Lonnie Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Paris</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sucharu Prakash</last_name>
      <email>sucharu.prakash@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Plano East</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Connor</last_name>
      <email>charles.connor@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology SA Medical Ctr</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Zweibach</last_name>
      <email>Alexander.Zweibach@USONCOLOGY.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Richards</last_name>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Wadlow</last_name>
      <email>raymond.wadlow@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onc and Hem Asso of SW VA Inc</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Kochenderfer</last_name>
      <email>Mark.Kochenderfer@USONCOLOGY.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Care Northwest, P.S.</name>
      <address>
        <city>Spokane Valley</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Miller</last_name>
      <phone>509-228-1188</phone>
      <email>Rose.Miller@ccnw.net</email>
    </contact>
    <investigator>
      <last_name>Danko Martincic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer SpecialistsPC</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cosgrove</last_name>
      <email>david.cosgrove@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ho, MD</last_name>
      <phone>7804328221</phone>
      <email>maria.ho@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Maria Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar - TUM</name>
      <address>
        <city>Munchen</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hana Alguel</last_name>
      <email>hana.alguel@mri.tum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk-Thomas Waldschmidt</last_name>
      <email>dirk-thomas.waldschmidt@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caritasklinik St. Theresia</name>
      <address>
        <city>Saarbruecken</city>
        <state>Saarland</state>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Lutz</last_name>
      <email>m.lutz@caritasklinikum.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukoelln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Wit</last_name>
      <email>maike.dewit@vivantes.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmd Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Pelzer</last_name>
      <email>uwe.pelzer@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Jassem</last_name>
      <email>jjassem@gumed.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>WSZ im. L. Rydygiera wToruniu</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Sawrycki</last_name>
      <email>piotrsaw@am.torun.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Zarrabeitia</last_name>
      <phone>+34942202525</phone>
      <email>ensayosonc@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Fernando Rivera Herrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iratxe Puebla</last_name>
      <phone>+34934894375</phone>
      <email>ipuebla@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Teresa Macarulla Mercade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Corcuera</last_name>
      <phone>+34914269394</phone>
      <email>acorcuera.hgugm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andres Muñoz Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Bertrand</last_name>
      <phone>+34917567984</phone>
      <email>cbertrand@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Cubillo Gracian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital U de Fuenlabrada</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Medina</last_name>
      <email>lmedina@cnio.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Pelaez</last_name>
      <phone>+34961973583</phone>
      <email>jpelaez@incliva.es</email>
    </contact>
    <investigator>
      <last_name>Andres Manuel Cervantes Ruiperez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Ross, MD</last_name>
      <email>paul.ross@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Paul Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kaur</last_name>
      <phone>+442032195294</phone>
      <email>anita.kaur@hcahealthcare.co.uk</email>
    </contact>
    <investigator>
      <last_name>Hendrik-Tobias Arkenau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Keogh</last_name>
      <phone>+4401619182100</phone>
      <email>rose.keogh@christie.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Richard Hubner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Watkins</last_name>
      <email>david.watkins@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Watkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Watkins</last_name>
      <email>david.watkins@rmh.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 12, 2016</lastchanged_date>
  <firstreceived_date>March 19, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Front-line Pancreatic Cancer</keyword>
  <keyword>Metastatic Pancreatic Cancer</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Nab-paclitaxel</keyword>
  <keyword>Abraxane</keyword>
  <keyword>Free IGF-1</keyword>
  <keyword>Heregulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
